Gilead Sciences (GILD) Other Non-Current Liabilities (2009 - 2026)

Gilead Sciences (GILD) has reported Other Non-Current Liabilities for 18 consecutive years, with $1.2 billion the latest figure, recorded in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.2 billion, down 10.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 10.25% YoY), and the FY2025 annual result was $896.0 million, up 7.95% from the prior year.
• Other Non-Current Liabilities was $1.2 billion for Q1 2026 at Gilead Sciences, up from $896.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $3.8 billion in Q1 2023 and troughed at $830.0 million in Q4 2024.
• Average Other Non-Current Liabilities over 5 years is $1.4 billion, with a median of $1.2 billion recorded in 2026.
• Year-over-year, Other Non-Current Liabilities surged 299.89% in 2023 and slumped 63.05% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $1.2 billion in 2022, then rose by 8.57% to $1.3 billion in 2023, then tumbled by 35.16% to $830.0 million in 2024, then gained by 7.95% to $896.0 million in 2025, then soared by 33.93% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $1.2 billion in Q1 2026, $896.0 million in Q4 2025, and $1.2 billion in Q3 2025.